Colombo N, Dubot C, Lorusso D, et al. - Patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab, showed significantly longer progression-free and overall survival in correlation with receiving pembrolizumab vs placebo, additionally.

• A double-blind, phase 3 trial.

• Patients were randomly assigned to receive pembrolizumab (200 mg) or placebo every 3 weeks for up to 35 cycles plus platinum-based chemotherapy and, per investigator discretion, bevacizumab.

• The pembrolizumab group and the placebo group had median progression-free survival of 10.4 months and 8.2 months, respectively.

• At 24 months, the two groups had overall survival of 53.0% and 41.7%, respectively